These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8212985)

  • 1. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An observation of the secretion of growth hormone and contraction of gall bladder after long-term use of growth-inhibition excitants].
    Zhu XF; Shi YF; Gao SM
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):87-91. PubMed ID: 8070297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment.
    Rhodes M; James RA; Bird M; Clayton B; Kendall-Taylor P; Lennard TW
    Scand J Gastroenterol; 1992; 27(2):115-8. PubMed ID: 1561523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.
    Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM
    Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallstones in acromegalic patients undergoing different treatment regimens.
    Schmidt K; Leuschner M; Harris AG; Althoff PH; Jacobi V; Jungmann E; Schumm-Draeger PM; Rau H; Braulke C; Usadel KH
    Clin Investig; 1992 Jul; 70(7):556-9. PubMed ID: 1356530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective study of functional changes in the gallbladder and formation of gallstones induced by long-term treatment of somatostatin analogue SMS201-995 in patients of active acromegaly].
    Zhu XF; Shi YF; Zhang JX
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):405-8, 455. PubMed ID: 1752152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones.
    Hussaini SH; Murphy GM; Kennedy C; Besser GM; Wass JA; Dowling RH
    Gastroenterology; 1994 Nov; 107(5):1503-13. PubMed ID: 7926514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four years' treatment of resistant acromegaly with octreotide.
    McKnight JA; McCance DR; Sheridan B; Atkinson AB
    Eur J Endocrinol; 1995 Apr; 132(4):429-32. PubMed ID: 7711880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
    Buscail LE; Puel-Bousquet C; Harris AG; Tauber JP; Escourrou JR; Delvaux MM; Vaysse NM; Bayard F; Ribet A
    Gastroenterol Clin Biol; 1991; 15(11):800-4. PubMed ID: 1769469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.